Press Releases
Results
showing 1-10 of 151
Court Decision Reinforces Constitutional Principles, But Does Not Relieve Humanitarian Crisis
A federal district court in Washington, DC, granted in part and denied in part a motion for a preliminary injunction in a lawsuit brought by AVAC and Journalism Development Network (JDN). The motion asked the court to allow humanitarian work to continue while the lawsuit challenging the administration’s foreign-assistance freeze moves forward.
Monday Payment Deadline Is a Step Towards Relief in Foreign Assistance Case
On behalf of plaintiffs AIDS Vaccine Advocacy Coalition and Journalism Development Network, Public Citizen attorneys appeared in court today to argue for a preliminary injunction against the Trump administration, to enable humanitarian work to continue while a lawsuit challenging the administration’s attempted termination of foreign assistance moves forward.
Trump Cannot Ignore The Law, SCOTUS Rules
The Supreme Court rejected the Trump administration’s efforts to evade compliance with a federal court’s order to lift the freeze on foreign assistance.
As Supreme Court Weighs Halt to Foreign Assistance Funding, Lives Hang in the Balance
The Trump administration’s last-minute plea asking the Supreme Court to override a temporary restraining order requiring the administration to keep its commitment to recipients of foreign assistance funding should be rejected, according to a brief filed today by Public Citizen Litigation Group on behalf of AVAC and Journalism Development Network.
Motion for Civil Contempt Filed in Foreign Aid Freeze Lawsuit
Today, on behalf of AVAC and the Journalism Development Network, Inc., Public Citizen Litigation Group filed a motion for civil contempt in its lawsuit seeking emergency relief from the freeze on foreign assistance funding and orders to stop work.
Critical Win In Lawsuit Against Trump Administration Over Foreign Aid Funding
A federal district court granted our motion for a temporary restraining order against the Trump administration’s wholesale freeze on foreign assistance funding. The order lifts the freeze and restores funding while our lawsuit against the administration moves forward.
Nonprofits Sue Trump Administration to Reverse Freeze on Foreign Aid Funding
Public Citizen filed a lawsuit in the US District Court for the District of Columbia against President Trump, the State Department, the US Agency for International Development (USAID), the Office of Management and Budget (OMB), Marco Rubio, Secretary State and Acting Administrator of USAID, and Russell Vought, Director of the Office of Management and Budget, on behalf of AVAC and Journalism Development Network, Inc. (JDN), seeking emergency relief from the freeze on funding for foreign assistance.
2024 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to Advocate who is Raising the Research Profile of Latin America
2024 Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to Advocate who is Raising the Research
National PrEP Advocates Applaud CDC PrEP Pilot Launch
Advocates applaud the announcement of the five jurisdictions to receive funding as part of a first-of-its-kind Centers of Disease Control and Prevention (CDC) PrEP pilot. The initiative has the potential to show how a National PrEP Program, as championed by advocacy organizations all over the US, could transform equitable PrEP access by greatly simplifying cost coverage, expanding access to providers, and creating more effective and community-driven education and awareness initiatives. PrEP4All, PrEP in Black America, HIVMA, and AVAC stand ready to work alongside key stakeholders in the five jurisdictions chosen—Baltimore, Houston, Florida, Oklahoma, and South Carolina—and provide insights from the last three years of multi-stakeholder discussions led by our organizations.
Prevention Option:
AVAC Calls on Gilead and Global Stakeholders to Accelerate Access to Generic Lenacapavir Following License Agreements
AVAC welcomes Gilead Sciences’ announcement in granting multiple, non-exclusive licenses to generic manufacturers to produce lenacapavir, their investigational twice-a-year injectable for PrEP, while it is still in clinical trials. This reflects longstanding community advocates’ calls to speed up access to PrEP options immediately following regulatory approval.
Prevention Option:
showing 1-10 of 151